A shot against decline: Shingles vaccine linked to lower dementia risk
A large retrospective cohort study of nearly 1.5 million US Medicare beneficiaries aged 65 and older has found that receipt of the two-dose recombinant zoster vaccine (RZV) is associated with a significantly reduced risk of new-onset dementia over a follow-up period of up to six years. Using weighted Cox proportional hazards models, researchers observed that vaccinated individuals had a 33% lower hazard of developing dementia within the first three years post-vaccination compared to matched unvaccinated controls, with a 26% reduction persisting beyond three years. The protective signal held across Alzheimer’s disease and vascular dementia subtypes, raising intriguing questions about the interplay between herpes zoster reactivation and chronic neurodegenerative processes.
Continue reading to unlock the full analysis, deeper implications, and why this study may matter for your field.
Unlock Full Briefing — 50% Off with Coupon: ERWMCWYU
Full version includes the complete summary, study significance, and direct link to the original source.
Stay curious. Stay informed — with Science Briefing.
This is a preview briefing. Upgrade to access the full version.
